Nanoscope Therapeutics to Present at the BIO International Convention

Nanoscope Therapeutics to Present at the BIO International Convention

DALLAS, May 29, 2024 —  Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that management will present at the BIO International Convention, taking place June 3-6, 2024, in San Diego, California.

Details for the presentations are as follows:

Session Date: Wednesday, June 5, 2024
Session Time: 4:30 – 4:45 p.m. PT
Location: San Diego Convention Center, Company Presentation Theater 1
Presenter: Sulagna Bhattacharya, Co-Founder and Chief Executive Officer

Ms. Bhattacharya presently serves on the board of directors of BIO. In her presentation, she will highlight Nanoscope’s Multi-Characteristic Opsin platform and give an overview of the Company’s mutation-agnostic approach. She will also detail the Company’s ongoing corporate activities. Nanoscope leadership will be available for meetings during the conference.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

On May 29, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.